1. Personal Information

First Name	Seong-Gyu
Last Name	KO
Affiliation	Kyung Hee University
Country	South Korea
Department	College of Korean Medicine
Degree (Ph.D. / M.D.)	M.D. Ph.D.
E-Mail	epiko@khu.ac.kr

2. Curriculum Vitae

- **Educational Background & Experience**

Year	Affiliation	Position
1985~1998	Kyung Hee University College of Korean Medicine, Seoul, Korea	MD, Master, PhD
2001~2004	Yonsei University Graduate School of Health Science and Management, Seoul, Korea.	M.P.H.
2003~2009	Seoul National University College of Medicine, Department of Tumor Biology, Seoul, Korea.	Ph.D
2023~	The Korean Academy of Science and Technology, KOREA	Board Member
2023~	Kyung Hee University College of Korean Medicine, Seoul, Korea	Dean

- **Publications**

No.	Contents
1	p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis. Cancer Cell Int. 2024 May 4;24(1):156.
2	SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway. Anticancer Res. 2024 May;44(5):1905-1913.
3	Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer. BMC Complement Med Ther. 2024 Feb 1;24(1):70.
4	Current Characteristics of Herbal Medicine Interventions for Cancer on Clinical Databases: A Cross-Sectional Study. Integr Cancer Ther. 2023 Jan-Dec;22:
5	Analgesic Effect of SH003 and Trichosanthes kirilowii</i> Maximowicz in Paclitaxel-Induced Neuropathic Pain in Mice. Curr Issues Mol Biol. 2022 Jan 31;44(2):718-730

3. Abstract

Lecture Title	**Biomarker Driven Korean Medicine Drug Development in the era of integrative cancer therapies**

SH003, a novel herbal formula derived from traditional Korean medicine, is emerging as a promising anticancer agent. It consists of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii. Preclinical studies have demonstrated its efficacy in inhibiting tumor growth and enhancing immune response through multiple signaling pathways, including apoptosis and angiogenesis. SH003 is also being investigated for its potential as a biomarker-driven therapy, targeting specific cancer biomarkers to improve treatment precision. Ongoing clinical trials aim to validate its safety and therapeutic potential. As part of a broader strategy to integrate traditional medicine with modern oncology, SH003 represents a significant advancement in targeted anticancer drug development.